Global Diagnostics Fapon positions as a global leading life sciences company with a strong focus on diagnostics and in-vitro diagnostics solutions across 68 countries. Sales opportunities exist in expanding IVD reagent and open instrument platform adoption, leveraging their one-stop raw materials, reagents, and platform offerings to existing and new lab networks.

AI in Therapeutics Advanced AI algorithm platforms and AI-engineered enzymes highlight a capability to improve assay sensitivity and workflow efficiency. Target opportunities include selling AI-optimized diagnostic reagents and enzyme solutions to biopharma and biotherapy developers seeking faster, more accurate testing and assay development.

New Product Rollout Recent launches such as ProPrime II, MeloScript III and Shine mT8000 indicate an ongoing cadence of high-throughput and sensitive diagnostic tools. Sales potential exists in bundling these with service contracts, training, and integration with customers’ existing LIMS and automation workflows.

Regional Expansions Active participation in global events from ADLM to MEDICA and WHX Labs Dubai underscores North American and Middle East presence. Leverage event-led introductions to target distributors, reference sites, and key accounts in regions with growing diagnostic demand and regulatory activity.

SMB–Midmarket Focus With 51-200 employees and revenue in the mid tens of millions, Fapon sits between large incumbents and small innovators. Approach midmarket labs and regional hospitals with scalable, cost-efficient IVD solutions, including open platforms, to capture share from larger bidders while offering tailored training and support.